retatrutide triple agonist clinical trial Research Guide: What the Phase 2 Data Reported (2026) Eli Lilly's Phase 3 clinical
Description
This combinatorial receptor signaling enables simultaneous modulation of multiple metabolic pathways
Understanding this mechanism helps manage it effectively
ClinicalTrials.gov (2025) 10
The results showed that retatrutide at the 8 mg dose reduced total body fat mass by 26.1% at 36 weeks, while the proportion of lean mass lost relative to total weight lost was consistent with other weight loss treatments
It is FDA-approved for weight management
But eating too littleespecially without knowing your metabolic needscan slow your metabolism and increase muscle loss
